Welcome to our dedicated page for Athersys news (Ticker: ATHX), a resource for investors and traders seeking the latest updates and insights on Athersys stock.
Athersys, Inc. (ATHX) is a clinical-stage biopharmaceutical company pioneering regenerative medicine therapies, with its lead investigational product MultiStem® targeting conditions like ischemic stroke and acute respiratory distress syndrome (ARDS). This page provides essential updates for stakeholders tracking the company’s scientific and corporate developments.
Access timely updates on clinical trial progress, regulatory milestones, strategic partnerships, and financial announcements. Our curated news collection helps investors and industry professionals stay informed about Athersys’ advancements in stem cell therapy and inflammatory disease treatments.
Key content includes updates on MultiStem® clinical studies, FDA communications, research collaborations, and pipeline expansion efforts. All information is sourced from verified channels to ensure accuracy and relevance.
Bookmark this page for streamlined access to Athersys’ latest developments. Check back regularly for objective reporting on innovations that could shape the future of regenerative medicine and impact long-term growth potential.
Athersys, Inc. (ATHX) announced positive topline results from the TREASURE ischemic stroke study conducted in Japan, showcasing the potential therapeutic impact of its MultiStem treatment. The study enrolled 206 patients and demonstrated improvements in functional independence, specifically mRS ≤2 and Barthel Index ≥95. Although the primary endpoint did not achieve statistical significance, long-term outcomes indicated continued improvement over one year. Athersys expressed confidence in the future success of its ongoing MASTERS-2 clinical trial.
Athersys, Inc. (NASDAQ: ATHX) announced that CEO Dan Camardo will participate virtually in the H.C. Wainwright Global Investment Conference from May 23-26, 2022, in Miami, Florida. The management team will also hold one-on-one meetings with institutional investors during this time. Interested investors can schedule meetings via provided email contacts. A presentation will be available on-demand starting May 24, 2022, at 7:00 a.m. ET on the Company's website, with an archived replay following the conference.
Athersys announced financial results for Q1 2022, revealing revenues of $2.9 million, up from zero the previous year.
The company's R&D expenses increased to $20.9 million, while G&A expenses significantly decreased to $4.1 million. The net loss narrowed to $22.2 million compared to $26.5 million in Q1 2021.
Athersys received FDA approval for bioreactor-manufactured MultiStem, enhancing production capabilities, and appointed Daniel A. Camardo as CEO. The company anticipates topline data from its TREASURE study in May, hosting a conference call to discuss results.
Athersys, Inc. (Nasdaq: ATHX) will participate in a fireside chat at the Bank of America Securities 2022 Global Healthcare Conference on May 11, 2022, at 4:00 p.m. PT in Las Vegas. CEO Dan Camardo and CFO Ivor Macleod will represent the company. Investors can schedule one-on-one meetings with the management during the conference. A live webcast will be available on the company’s website, with an archived replay accessible afterward. Athersys focuses on developing therapeutic products, notably the MultiStem® cell therapy for various medical conditions.
Athersys, Inc. (NASDAQ: ATHX) will release its Q1 2022 financial results on May 6, 2022, at 8:00 a.m. EDT. This announcement coincides with the upcoming topline data from its partner, HEALIOS K.K., regarding the Phase 2/3 TREASURE study, which evaluates MultiStem® (invimestrocel, HLCM051) for ischemic stroke treatment. Following this data release, Athersys will hold an investor conference call to discuss the results and future implications for its clinical trials.
Athersys announced significant updates regarding its partnership with Healios K.K. for the MultiStem cell therapy. The last 365-day follow-up visit in the Phase 2/3 TREASURE study for ischemic stroke has been completed, marking a key milestone. Topline results are expected in May 2022. Healios is also in discussions with Japan's PMDA regarding the ARDS program, although additional data is required for approval, delaying application plans. Athersys remains optimistic about the potential of MultiStem therapy, evidenced by its ongoing MACOVIA study for ARDS patients.
Athersys, Inc. (NASDAQ: ATHX) announces presentations at two upcoming healthcare conferences: the Locust Walk Stem Cell Conference on April 11, 2022, and the Needham Healthcare Conference on April 13, 2022. President B.J. Lehmann will present on MultiStem®, a cell therapy in late-stage clinical development for ischemic stroke and ARDS. CEO Dan Camardo will outline clinical programs and commercialization strategies. Live webcasts of both events will be available online, with recordings accessible afterward.
Athersys announced its financial results for Q4 and full year 2021, reporting revenues of $5.5 million, a significant increase from $1.4 million in 2020. The company experienced a net loss of $87 million for the year, compared to $78.8 million in the previous year. CEO Dan Camardo highlighted the potential of MultiStem in cell therapy, especially following positive data from clinical trials. The company also strengthened its partnership with Healios, which is critical for regulatory submissions in Japan.
Athersys (NASDAQ: ATHX) appointed Daniel Camardo as CEO, offering him a significant inducement package. He received nonqualified stock options to purchase 10 million shares at an exercise price of $0.86, the closing price of the stock on his start date, February 14, 2022. The options vest in part over four years and relate to company milestones including regulatory approvals and sales achievements. Athersys focuses on biotherapeutic developments, particularly the MultiStem cell therapy, targeting multiple critical care indications.
Athersys, Inc. (NASDAQ: ATHX) will release its Q4 and full year 2021 financial results on
FAQ
What is the market cap of Athersys (ATHX)?
